Table 3.

Representative studies of ESI-MS technologies for the non-covalent interactions between small drug molecules and polypeptides.

Subjects	Ligands	Type of MS	References
Insulin	Phosphorylated daidzein derivatives	ESI-MS	Chen et al., 2008
Angiotensin peptide	Gold ion	FT-ICR-ESI-MS	Lee et al., 2012
18 α-amino acids	5 Ginsenosides	ESI-QT MS	Qu et al., 2009
Amyloid-β-peptide	Oleuropein	FT-ICR-ESI-MS	Bazoti et al., 2008
Amyloid-β-peptides	Nicotine, melatonin, 5- hydroxy-N-acetyltryptamine, daunomycin, doxorubicin	ESI-MS	Skribanek et al., 2001
Cell wall glycopeptides	Vancomycin, ristocetin	ESI-MS	Lim et al., 1995
Salivary proline-rich peptides	Catechin and its derived compounds	ESI-MS	Sarni-Manchado and Cheynier, 2002